BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...
Brittany Pieniazek knew she had a chance of developing breast cancer. The Dyer resident’s mother and aunt had both been ...
Hosted on MSN4h
I was diagnosed with an aggressive cancer at 36. Ten years later, I'm still learning to be confident in my body.It really hurt, and that's when I discovered a lump on my left breast. At this point ... but it took six months for me to ...
DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
We also are finalizing plans to begin the expansion portion of our trial, with an initial focus on patients with ...
Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...
Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback